Literature DB >> 19934372

Quantitative loci regulating plasma levels of gamma glutamyl transferase and albumin and their genetic correlations with cardiovascular risk factors.

Tanushree Bose1, V Saroja Voruganti, M Elizabeth Tejero, J Michael Proffitt, Laura A Cox, John L VandeBerg, Michael C Mahaney, Jeffrey Rogers, Jeanne H Freeland-Graves, Shelley A Cole, Anthony G Comuzzie.   

Abstract

gamma Glutamyl transferase (GGT) and albumin (ALB) are two markers of liver function. These two proteins have been associated with non-alcoholic fatty liver disease and cardiovascular disease. The objectives of this study were to explore the genetic factors that influence variation in the plasma levels of GGT and ALB and to evaluate their genetic correlations with cardiovascular risk factors. Baboons from the Southwest National Primate Research Center at the Southwest Foundation for Biomedical Research, San Antonio, TX, were used as an animal model. The baboons were fed a standard monkey chow diet ad libitum. Fasting plasma concentrations of GGT, ALB, triglycerides, total cholesterol and LDL cholesterol were measured in 350 pedigreed adult baboons by standard assay procedures. A maximum likelihood-based variance decomposition approach implemented in the computer program SOLAR was used to conduct genetic analyses. The heritabilities of GGT (h(2) = 0.55; P < 0.0001) and ALB (h(2) = 0.42; P < 0.01) were significant. No statistically significant associations were found between GGT and the cardiovascular-related phenotypes. Genetic correlations between ALB and total cholesterol, LDL cholesterol and triglycerides were significant. A QTL (LOD = 2.8) for GGT plasma levels was identified on the baboon homologue of human chromosome 22 between markers D22S304 and D22S280. A QTL (LOD = 2.3) near marker D10S1432 was detected on the baboon homologue of human chromosome 10 for ALB. These results imply that variations in the plasma levels of GGT and ALB are under significant genetic regulation and that a common genetic component influences ALB and cardiovascular risk factor phenotypes.

Entities:  

Keywords:  NAFLD; atherosclerosis; genome scan; obesity; oxidative stress

Mesh:

Substances:

Year:  2009        PMID: 19934372      PMCID: PMC2832911          DOI: 10.3181/0903-RM-115

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  41 in total

Review 1.  Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens.

Authors:  G Targher
Journal:  Diabet Med       Date:  2007-01       Impact factor: 4.359

Review 2.  Non-alcoholic fatty liver disease and increased risk of cardiovascular disease.

Authors:  Giovanni Targher; Guido Arcaro
Journal:  Atherosclerosis       Date:  2006-09-12       Impact factor: 5.162

3.  Serum gamma-glutamyl transpeptidase is a determinant of insulin resistance independently of adiposity in Pima Indian children.

Authors:  Emilio Ortega; Juraj Koska; Arline D Salbe; Pietro Antonio Tataranni; Joy C Bunt
Journal:  J Clin Endocrinol Metab       Date:  2006-01-24       Impact factor: 5.958

4.  Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.

Authors:  Giovanni Targher; Lorenzo Bertolini; Felice Poli; Stefano Rodella; Luca Scala; Roberto Tessari; Luciano Zenari; Giancarlo Falezza
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

5.  Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study.

Authors:  Roger K Schindhelm; Jacqueline M Dekker; Giel Nijpels; Lex M Bouter; Coen D A Stehouwer; Robert J Heine; Michaela Diamant
Journal:  Atherosclerosis       Date:  2006-05-08       Impact factor: 5.162

6.  Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults.

Authors:  Elfriede Ruttmann; Larry J Brant; Hans Concin; Günter Diem; Kilian Rapp; Hanno Ulmer
Journal:  Circulation       Date:  2005-09-26       Impact factor: 29.690

7.  gamma-Glutamyltransferase predicts cardiovascular death among Japanese women.

Authors:  Atsushi Hozawa; Tomonori Okamura; Takashi Kadowaki; Yoshitaka Murakami; Koshi Nakamura; Takehito Hayakawa; Yoshikuni Kita; Yasuyuki Nakamura; Akira Okayama; Hirotsugu Ueshima
Journal:  Atherosclerosis       Date:  2006-10-10       Impact factor: 5.162

8.  Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study.

Authors:  Douglas S Lee; Jane C Evans; Sander J Robins; Peter W Wilson; Irene Albano; Caroline S Fox; Thomas J Wang; Emelia J Benjamin; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-11-09       Impact factor: 8.311

Review 9.  Recent concepts in non-alcoholic fatty liver disease.

Authors:  L A Adams; P Angulo
Journal:  Diabet Med       Date:  2005-09       Impact factor: 4.359

10.  Genome-wide scan of resistin mRNA expression in omental adipose tissue of baboons.

Authors:  M E Tejero; S A Cole; G Cai; K W Peebles; J H Freeland-Graves; L A Cox; M C Mahaney; J Rogers; J L VandeBerg; J Blangero; A G Comuzzie
Journal:  Int J Obes (Lond)       Date:  2005-04       Impact factor: 5.095

View more
  3 in total

Review 1.  Nonhuman Primates and Translational Research-Cardiovascular Disease.

Authors:  Laura A Cox; Michael Olivier; Kimberly Spradling-Reeves; Genesio M Karere; Anthony G Comuzzie; John L VandeBerg
Journal:  ILAR J       Date:  2017-12-01

2.  Neutrophil membrane-mimicking nanodecoys with intrinsic anti-inflammatory properties alleviate sepsis-induced acute liver injury and lethality in a mouse endotoxemia model.

Authors:  Yao Xiao; Chao Ren; Gan Chen; Pan Shang; Xiang Song; Guoxing You; Shaoduo Yan; Yongming Yao; Hong Zhou
Journal:  Mater Today Bio       Date:  2022-03-16

3.  The baboon kidney transcriptome: analysis of transcript sequence, splice variants, and abundance.

Authors:  Kimberly D Spradling; Jeremy P Glenn; Roy Garcia; Robert E Shade; Laura A Cox
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.